Zydus Lifesciences has received USFDA approval to market Lacosamide Tablets, a generic anti-epileptic medication, in multiple strengths. The drug will be manufactured at the group's facility in Moraiya, Ahmedabad.
Photograph: Courtesy Zydus.
New Delhi, Dec 16 (PTI) Zydus Lifesciences on Saturday said it has received approval from the US health regulator to market a generic anti-epileptic medication.
The company has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Lacosamide Tablets in multiple strengths, the drug firm said in a statement.
Lacosamide is indicated to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures.
The company said it will manufacture the product at the group's formulation manufacturing facility in Moraiya, Ahmedabad.
As per IQVIA data, Lacosamide Tablets had annual sales of USD 249 million in the US.
Home » Market News » Zydus Lifesciences Gets USFDA Nod for Generic Anti-Epileptic Drug
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback